Biotechnology The ACTIV-3 clinical trial is being run by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is the only study evaluating the efficacy of Eli Lilly’s bamlanivimab in hospitalized COVID-19 patients, the US pharma major announced, following mention in its financial results media call when a pause of the trial was discussed. 28 October 2020